Press Release: OncoFusion Therapeutics : Medivation Enters Into License Agreement With OncoFusion for Compounds Targeting Bromodomain Proteins

SAN FRANCISCO, CA and ANN ARBOR, MI--(Marketwired - Apr 23, 2014) - Medivation, Inc. (NASDAQ: MDVN) and OncoFusion Therapeutics, Inc. today announced that they have entered into a research and license agreement for certain compounds targeting Bromodomain and Extra-Terminal (BET) proteins for potential use in oncology and other disease areas. Medivation will gain exclusive worldwide rights for the development and commercialization of these compounds. Under the terms of the agreement, Medivation shall have access to OncoFusion's growing library of small molecule BET bromodomain inhibitor compounds from which Medivation may select compounds to move forward into drug development efforts.